ADVANZ PHARMA

What ADVANZ PHARMA does

ADVANZ PHARMA is a privately held, London-headquartered specialty pharmaceutical company that develops and commercialises complex medicines — innovative medicines, specialty generics, biosimilars, and originator brands — across therapeutic areas including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and rare diseases. Its operational footprint spans commercial sales in more than 90 countries, with a direct commercial presence in more than 20 markets across Europe, Canada, and Australia, complemented by a Centre of Excellence in Mumbai, India, and a global distribution and commercialisation partner network of more than 300 counterparties. Core recent assets include the Gobivaz (golimumab biosimilar to Simponi) and the Eylea (aflibercept) biosimilar pipeline built through a strategic co-development partnership with Alvotech, alongside a specialty generics portfolio (deferiprone, levothyroxine, methotrexate, lenalidomide, carbimazole, digoxin, chloromycetin, levofloxacin, omega-3-acid ethyl ester, emtricitabine/tenofovir, vernakalant) and originator brands such as Brinavess, Progynova, and Ilomedin.

The company monetises through pharmaceutical product sales under one-time licence economics, generating revenue from sales of its specialty, hospital, and rare disease medicines through both direct enterprise field sales in its owned geographies and channel/distributor partnerships elsewhere; pricing is not publicly disclosed. The parent entity, ADVANZ PHARMA CORP. Limited, is incorporated in Jersey, UK, with ADVANZ PHARMA Services (UK) Limited operating as a wholly-owned subsidiary in England. As of January 2026, the company is operating under a formal sale process pursuant to the UK City Code on Takeovers and Mergers, indicating active consideration of an ownership transition, and has recently executed portfolio-accretive deals including the December 2025 acquisition of Progynova/Cyclo-Progynova EMEA rights and global Ilomedin rights.

Name

ADVANZ PHARMA

Legal name

ADVANZ PHARMA CORP. Limited

Website

https://concordiarxinternational.com

Company type

Private

Operating status

Operating

Short description

ADVANZ PHARMA is a London-headquartered, privately held specialty pharmaceutical company that develops and commercialises innovative medicines, specialty generics, biosimilars, and originator brands across more than 90 countries, serving patients with hepatology, gastroenterology, anti-infective, critical care, endocrinology, oncology, CNS, and rare disease conditions.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Specialty pharmaceuticals
• Hospital medicines
• Rare disease treatments
• Biosimilar development
• Pharmaceutical commercialization

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of specialty, hospital, and rare disease medicines including innovative medicines, specialty generics, biosimilars, and originator brands.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

ADVANZ PHARMA develops and commercialises specialty, hospital, and rare disease medicines, including innovative medicines, specialty generics, biosimilars, and originator brands. The portfolio spans therapeutic areas such as hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and rare diseases. The company acts as a partner of choice for innovative biopharma and pharmaceutical development companies across more than 90 countries globally.

Product overview

ADVANZ PHARMA is a global specialty pharmaceutical company that commercialises specialty, hospital, and rare disease medicines. The company's product portfolio comprises three main categories: innovative medicines, specialty generics & biosimilars, and originator brands. The portfolio covers therapeutic areas including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and rare diseases. The company is rapidly building a diverse biosimilars portfolio through a partnership with Alvotech, including products such as Gobivaz® (golimumab biosimilar) and Mynzepli (aflibercept biosimilar), aimed at expanding treatment options and reducing healthcare costs. The company operates with commercial sales in more than 90 countries globally.

Differentiator

Problem solved

Functional benefit

Brands

• Gobivaz: A biosimilar to Simponi (golimumab) developed in partnership with Alvotech, received marketing approval across the European Economic Area
• MYNZEPLI
• Brinavess

Segments1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• AlvotechcoreStrategic or Co-development Partner · 30 January 2026ADVANZ PHARMA partnered with Alvotech for the development and commercialisation of biosimilar products. The partnership includes Eylea (aflibercept) biosimilar and Gobivaz (golimumab biosimilar). Marketing approvals have been received for Gobivaz across the European Economic Area and from MHRA.
• Innovative Biopharma CompaniescoreStrategic or Co-development PartnerADVANZ PHARMA partners with innovative biopharma and pharmaceutical development companies to bring medicines to patients worldwide. The company works with more than 300 partners in production, development, portfolio licensing, and commercialisation.
• Healthcare ProfessionalscoreOthersADVANZ PHARMA engages with healthcare professionals for professional purposes including clinical trial participation, advisory engagements, scientific collaboration, and compliance with transparency obligations.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Alvotech: Biosimilar developer partnered with ADVANZ PHARMA on Eylea and Gobivaz, with overlapping focus on specialty biologic/biosimilar products and shared commercial economics in Europe and other ADVANZ markets.
• Hikma Pharmaceuticals: UK-headquartered specialty and generic pharmaceutical company with a comparable portfolio spanning specialty generics, hospital injectables, and biosimilars sold across Europe, the Middle East, and North America.
• Stada Arzneimittel: European-focused specialty generics and consumer healthcare company, similarly operating a partner-of-choice model for biosimilars and specialty products across hospital and retail channels.
• Mallinckrodt: Specialty pharmaceutical company with hospital-focused brands, specialty generics, and rare disease exposure — overlapping with ADVANZ's specialty, hospital, and rare disease therapeutic areas.
• Endo International: Specialty pharma with branded and generics portfolios spanning endocrinology, oncology, and rare diseases — directly comparable therapeutic-area coverage and product mix to ADVANZ PHARMA.

Broad incumbents

• Viatris: Large global pharmaceutical company with established specialty, biosimilar, and generics franchises across Europe and worldwide — a much broader incumbent but overlapping significantly with ADVANZ's product and market footprint.
• Sandoz (Novartis): Global leader in biosimilars and generics with significant European and global commercial reach, representing a much larger but directly comparable incumbent in the same biosimilar/specialty generic space.
• Teva Pharmaceutical Industries: Global specialty and generics powerhouse with European commercial scale and biosimilar capabilities — overlapping with ADVANZ's specialty generics and biosimilar portfolio across the same hospital and specialty channels.

Emerging players

• Glenmark Pharmaceuticals: India-based specialty generics and biosimilars player expanding in Europe and emerging markets, with comparable product categories though smaller commercial scale in ADVANZ's core European markets.
• Aspen Pharmacare: Global specialty and generics pharmaceutical company with European and emerging-market presence, comparable in therapeutic-area breadth though more concentrated in branded specialty and regional generics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/advanz-pharma/about

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ADVANZ PHARMA